Objective:To observe the inhibitory effect of Jiawei Jinning formula on postoperative recurrence of ground-glass early lung cancer. MethodsSeventy-two patients with ground-glass early lung cancer were randomly divided into treatment group and control group after operation, 36 cases in each group. The treatment group was administered Jiawei Jinning formula, while the control group was administered 1/20 dose of Jiawei Jinning formula. Both groups were treated continuously for 1 year or until the disease progression occurred to observe response evaluation in solid tumors and immune efficacy, as well as the comparison of the changes of TCM syndrome scores.  Results:①During the trail, there were 3 dropout cases in the treatment group and 3 dropout cases in the control group, and 66 cases finally completed the test, 33 cases in each group. ②Response evaluation in solid tumor: within one year after operation, the disease control rates of the treatment group and the control group were 93.94% and 72.73%, respectively. The curative effect of treatment group was better than that of control group (P<0.05). ③Immune efficacy: three months after operation, the effective rates of the treatment group and the control group were 75.76% and 69.70%, respectively. There was no significant difference in immune efficacy between the two groups (P>0.05). Comparisons of the immune efficacy were made between the two groups 6 months, 9 months and 12 months after operation respectively, and each time the treatment group showed better immune efficacy than that of the control group (P<0.05). ④ After treatment, the TCM syndrome scores in the two groups showed a continuous downward trend, and the difference was statistically significant compared with the scores in the previous observation time point (P<0.05). Comparisons of TCM syndrome scores between the two groups 6 months, 9 months and 12 months after operation showed that TCM syndrome scores in the treatment group was lower than those in the control group (P<0.05).  Conclusion:Jiawei Jinning formula can inhibit the postoperative recurrence of ground-glass early lung cancer to some extent, contribute to the recovery of immune function and improve TCM syndromes, which is worthy of clinical application.